Clinical TrialApr 27, 2026, 08:31 AM
TNYA to Present New TN-401 RIDGE-1 Phase 1b/2 Data at ASGCT
AI Summary
Tenaya Therapeutics announced multiple abstract acceptances for the ASGCT Annual Meeting in May 2026. The highlight is a late-breaking oral presentation of new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial for TN-401, a gene therapy for PKP2-associated ARVC. This presentation will include one-year Cohort 1 results and early Cohort 2 data on safety, biopsy, and efficacy. Additionally, the company will present two posters on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 for PLN-R14del-associated DCM. A webcast conference call is planned to discuss the TN-401 data.
Key Highlights
- TNYA to present RIDGE-1 Phase 1b/2 TN-401 data at ASGCT May 11-15, 2026.
- Data includes one-year Cohort 1 results and early Cohort 2 data.
- Safety, biopsy, efficacy data from 3E13 vg/kg and 6E13 vg/kg doses.
- TN-401 is an AAV9 gene therapy for PKP2-associated ARVC.
- Two additional posters accepted for ASGCT 2026.
- One poster on parental perceptions of gene therapy for children.
- Second poster on TN-501 gene editing therapy for PLN-R14del DCM.
- Webcast conference call planned to discuss TN-401 data.